A hopeful prospect of riociguat as a soluble guanylate cyclase stimulator for management of pressure ulcers.

A hopeful prospect of riociguat as a soluble guanylate cyclase stimulator for management of pressure ulcers. Curr Drug Discov Technol. 2017 Sep 15;: Authors: Azadi S, Ashrafi H, Azadi A Abstract Pressure ulcer remains as a common problem, especially developed in disabled patients and hence, subjected to continuous pressure for prolonged periods of time. Most of the studies investigating the preventive and therapeutic approaches have focused on wound cleansing, dressing and supportive strategies , as well as pharmacological therapy including zinc sulphate, vitamin A or phenytoin. Despite such efforts, pressure ulcer continues to impair the life quality and expectancy. Thus involving in the paradigm shift in biomedical studies, the recent ones focus on biological signaling pathways involving nitric oxide (NO)- soluble guanylatecyclase (sGC)- cyclic guanosine monophosphate (cGMP) contributing in vasodilation, reperfusion and oxygen delivery. NO is an important signaling molecule activating sGC and cGMP production, which is a mediator of vasodilation and platelet inhibition, respectively. Considering the subject, it could be hypothesized that the application of sGC stimulators and activators is a very curious strategy for pressure ulcer healing.. It is well known that pressure and shear forces usually produce the blood vessel obstruction, inducing ischemia and tissue necrosis and in pathologic states, damaged endotheliumleads to a reduce...
Source: Current Drug Discovery Technologies - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Discov Technol Source Type: research